Clinical Trial Update: Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs. [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluated the efficacy and safety of the MNI-672 SPECT imaging agent for detecting cerebral beta-amyloid in Alzheimer's disease patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MNI-672 SPECT imaging agent (MNI-672)

Snippet

Sponsor: Molecular NeuroImaging | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED